Heron Therapeutics, Inc. (HRTX) Guidance & Earnings Results
On 2026-08-10 Heron Therapeutics, Inc. lowered guidance: "Withdrew full-year 2026 guidance for net product sales and Adjusted…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
HRTXHeron Therapeutics, Inc.Follow HRTX — free
—
Price chart with a free account
- Market cap
- 57.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 10 Aug 26 | Lowered | Withdrew full-year 2026 guidance for net product sales and Adjusted EBITDA · full year |
| 11 May 26 | Reaffirmed | FY2026 net revenue $173M-$183M, Adjusted EBITDA $10M-$20M · full year |
| 26 Feb 26 | Raised | FY2026 net revenue guidance $173-$183M vs FY2025 actual $154.9M; adjusted EBITDA $10-$20M. · full year |
| 4 Nov 25 | Reaffirmed | Net Revenue $153M-$163M; Adjusted EBITDA $9M-$13M · full year |
| 8 Aug 25 | Raised | FY2025 Net Revenue $153M-$163M (reaffirmed); FY2025 Adjusted EBITDA raised to $9M-$13M from $4M-$12M · full year |
Heron Therapeutics, Inc. — questions
- What guidance did Heron Therapeutics, Inc. give?
- On 2026-08-10: "Withdrew full-year 2026 guidance for net product sales and Adjusted EBITDA"
- When does Heron Therapeutics, Inc. report earnings?
- Heron Therapeutics, Inc.'s next earnings report is expected on 2026-11-10.
Every figure on this page comes from Heron Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.